Illumina Launches StrataMap Spatial Solution to Advance Spatial Transcriptomics Research
Published: 30 Jun 2026
Author: Rohan Patil
Global leader in genomic sequencing technologies, Illumina announced the launch of the StrataMap Spatial Solution, an end-to-end sequencing-based platform for research that will enable researchers to take a dramatic new leap forward in the field of spatial transcriptomics. The new solution allows scientists to take an incredibly sensitive picture of the structure, analyse its function, study tumour evolution, and find new drug targets.
Advancing Spatial Biology Through High-Resolution Transcriptomics
The StrataMap Spatial Solution is designed to provide scientists with an incredibly powerful tool for studying tissue architecture and cellular relationships with high sensitivity, flexible capture areas to fit the experiment, and single-cell resolution. The solution, which is used in Illumina's DRAGEN bioinformatics pipeline and Connected Multiomics platform, simplifies downstream applications with machine learning-driven cell segmentation and transcript assignment, and provides enriched biological interpretation.
The StrataMap Spatial helped map understandings and understanding how tumours develop, said Steve Barnard, Chief Technology Officer of Illumina, “and proved as a valuable component in building an insight ecosystem where data-at-scale is discovery without boundaries.”
According to Precedence Research, the molecular biology enzymes, reagents, and kits market size was calculated at USD 27.68 billion in 2025 and is predicted to increase from USD 30.36 billion in 2026 to approximately USD 68.86 billion by 2035, expanding at a CAGR of 9.54% from 2026 to 2035 as the demand for sophisticated genomic technologies, precision medicine, and molecular diagnostics increases.
Industry Impact and Outlook
StrataMap Spatial is intended to meet the demand for scalable spatial biology technologies in life sciences and biopharmaceutical research, and represents StrataMap's first attempt at spatial biology product development. The platform should greatly speed up the discovery process in oncology, neuroscience, and developmental biology and increase the understanding of complex disease mechanisms.
As investment in the field continues to rise, the market is also seeing growth with spatial biology, AI-empowered bioinformatics, and automation set to boost the efficiency and prospects of research in the field across the pharmaceutical, biotechnology, and academic research & development markets.